Pilot Study of the Human Metagenome in Metabolic Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-08-14

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a cohort study to understand the role of the human metagenome, and associated metabolites, in health and in various diseased states, in particular obesity as well as sarcopenia.

Recruited participants will have their fecal, salivary, urine, serum, and in certain instances, mucosal samples taken, for metagenomic sequencing and metabolite testing.

We hope to uncover various differences and signatures in the metagenome and metabolome in various diseased states, with potential future therapeutic applications in personalised medicine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Characterization of Gut Microbiota in Chronic Liver Disease With Decreased Muscle Mass

NCT05729269

Gastrointestinal Microbiome Sarcopenia Liver Disease Chronic

COMPLETED

To Investigate the Influence of Ethnicity in Metabolic Disease in Healthy, Overweight and Obese Subjects

NCT00988819

Healthy Overweight Obesity

UNKNOWN

The Effects of Environmental Factors on the Macro-genome and Metabolism of Obese Patients.

NCT06673433

Obesity and Overweight

ACTIVE_NOT_RECRUITING

Molecular, Cellular, and Genetic Characterization of Human Adipose Tissue and Its Role in Metabolism

NCT02692885

Brown Adipose Tissue (BAT) Physiology Phenotyping Brown Adipocytes

RECRUITING

Analysis of Metabolic State in Normal-weight and Overweight-obese After Lifestyle Improvement and/or Weight Loss

NCT04402697

Overweight and Obesity

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The human metagenome comprises all nucleotide sequences isolated from all organisms living on and within an individual and has been shown to have significant alterations in relation to certain diseased states related to chronic inflammation, such as obesity and sarcopenia.

The gut bacteriome, and more recently the virome, has been shown to be significantly correlated with the obese phenotype, while gut microbiome dysbiosis is known to occur in individuals with sarcopenia. Clinically, there is an unmet clinical need to better personalize the treatment of patients with metabolic disorders such as obesity and metabolic syndrome, and patients suffering from sarcopenia and frailty as a result of aging. However, the literature regarding the metagenomic signatures associated with these disorders, in particular the non-bacteriome species, bacterial metabolites, and their relationship with host metabolism, were scarce.

Thus we hypothesize, that the human metagenome and metabolome, may play a role in influencing chronic inflammatory disorders related to metabolic disorders, such as obesity and diseases related to aging like sarcopenia and aging.

This is a cohort study, involving metagenomic sequencing and metabolomic analysis, of patients metagenome and metabolome, in various diseased states. A cohort of healthy control patients without obesity or sarcopenia will also be recruited.

Samples collected will include fecal, salivary, serum, urine, mucosal samples for metagenomic sequencing and metabolomic testing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Sarcopenia Sarcopenic Obesity Chronic Inflammation Metabolic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

* Obese (BMI\>27.5kg/m2)

* Sarcopenic patients, defined as 1) low handgrip strength (\<26 for males; \<18kg for females), AND/OR low gait speed (\<0.8m/s) AND low muscle mass (\<7.0kg/m2 for males; \<5.7kg/m2 for females)

\- Healthy subjects without sarcopenia, and not obese (BMI\<27.5kg/m2)